| 0.8808 0.02 (2.28%) | 10-24 14:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.13 | 1-year : | 1.27 |
| Resists | First : | 0.97 | Second : | 1.08 |
| Pivot price | 0.94  |
|||
| Supports | First : | 0.77 | Second : | 0.64 |
| MAs | MA(5) : | 0.91 |
MA(20) : | 0.91 |
| MA(100) : | 0.76 |
MA(250) : | 0.83 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.6 |
D(3) : | 39.4 |
| RSI | RSI(14): 48.7 |
|||
| 52-week | High : | 1.48 | Low : | 0.44 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ACET ] has closed above bottom band by 19.6%. Bollinger Bands are 13.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.92 - 0.93 | 0.93 - 0.93 |
| Low: | 0.84 - 0.85 | 0.85 - 0.85 |
| Close: | 0.85 - 0.87 | 0.87 - 0.88 |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Thu, 16 Oct 2025
First patient dosed: Adicet Bio's ADI-001 begins Phase 1 trial in treatment‑refractory RA; data 2H/2026 - Stock Titan
Wed, 08 Oct 2025
Guggenheim Maintains Adicet Bio (ACET) Buy Recommendation - Nasdaq
Wed, 08 Oct 2025
Adicet Bio stock holds steady as Citizens reiterates Market Perform - Investing.com
Tue, 07 Oct 2025
Adicet Bio Receives Nasdaq Extension for Compliance - TipRanks
Tue, 07 Oct 2025
Adicet Bio Reports Promising Phase 1 Study Results - TipRanks
Tue, 07 Oct 2025
Guggenheim raises Adicet Bio stock price target on positive lupus data - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 153 (M) |
| Shares Float | 68 (M) |
| Held by Insiders | 2.7 (%) |
| Held by Institutions | 60.9 (%) |
| Shares Short | 4,780 (K) |
| Shares Short P.Month | 4,580 (K) |
| EPS | -1.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.45 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.6 % |
| Return on Equity (ttm) | -64.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -98 (M) |
| Levered Free Cash Flow | -57 (M) |
| PE Ratio | -0.68 |
| PEG Ratio | 0 |
| Price to Book value | 0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.38 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|